Linden Thomas Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Linden Thomas Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$702K	Sell	12,277 -26	-0.2%	-$1.42K	0.06%	383
2026 Q1	$695K	Buy	+12,303	New	+$717K	0.07%	358
2024 Q2	–	Sell	-17,900	Closed	-$1.56M	–	453
2024 Q1	$1.56M	Buy	17,900 +17	+0.1%	+$1.52K	0.25%	151
2023 Q4	$1.72M	Sell	17,883 -166	-0.9%	-$14.7K	0.32%	105
2023 Q3	$1.6M	Sell	18,049 -542	-3%	-$48.2K	0.36%	84
2023 Q2	$1.61M	Buy	18,591 +80	+0.4%	+$7.53K	0.36%	87
2023 Q1	$1.8M	Buy	18,511 +459	+3%	+$47.6K	0.45%	58
2022 Q4	$1.87M	Buy	+18,052	New	+$1.69M	0.53%	40

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Linden Thomas Advisory Services's BMRN Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its BioMarin Pharmaceuticals (BMRN) stake by 0.21% in Q2 2026, selling an estimated $1.42K and leaving 12,277 shares worth $702K. The position accounts for 0.06% of the portfolio, ranked #383.

Linden Thomas Advisory Services first reported a position in BMRN in Q4 2022 and has held it in 8 quarters since. The position peaked at $1.87M in Q4 2022. 112 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Linden Thomas Advisory Services held 12,277 shares of BioMarin Pharmaceuticals worth $702K as of Q2 2026.
Linden Thomas Advisory Services sold 26 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.42K.
BioMarin Pharmaceuticals made up 0.06% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #383 holding.
Linden Thomas Advisory Services first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Linden Thomas Advisory Services's BioMarin Pharmaceuticals position peaked at $1.87M in Q4 2022.
112 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.